TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12756423

Group type: EXPERIMENTAL
Intervention: Drug-herb interaction pairs involving herbal products and drugs
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: St. John's wort
Number of subjects: 22
Study: 11019879

Group type: EXPERIMENTAL
Intervention: Tscherning aberrometer
Number of subjects: 300
Study: 8701626

Group type: EXPERIMENTAL
Intervention: Danazol (600 mg/die)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: GnRH‐analogon (Decapeptyl‐Depot)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no pretreatment)
Number of subjects: 40
Study: 1627048

Group type: EXPERIMENTAL
Intervention: Epinephrine infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 0
Study: 6430811

Group type: EXPERIMENTAL
Intervention: Molsidomine (2 mg 4 times daily)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Isosorbide dinitrate (10 mg 4 times daily)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 31082447

Group type: EXPERIMENTAL
Intervention: Large portions of unhealthy snacks
Number of subjects: 511

Group type: COMPARATOR
Intervention: Small portions of unhealthy snacks
Number of subjects: 511
Study: 30395548

Group type: EXPERIMENTAL
Intervention: Daily Right Unilateral Ultrabrief ECT (RULUB)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Bitemporal ECT (BT)
Number of subjects: 214
Study: 27161974

Group type: EXPERIMENTAL
Intervention: 2 years of adjuvant tamoxifen (n = 276)
Number of subjects: 564

Group type: COMPARATOR
Intervention: No systemic treatment (n = 288)
Number of subjects: 564
Study: 25126866

Group type: EXPERIMENTAL
Intervention: Anti-smoking awareness programme (health talks, information leaflets, and posters)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-smoking awareness programme
Number of subjects: 0
Study: 22446170

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 420

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Dapagliflozin plus pioglitazone
Number of subjects: 420

Group type: COMPARATOR
Intervention: Pioglitazone alone
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 420

Group type: COMPARATOR
Intervention: Placebo plus pioglitazone
Number of subjects: 420
Study: 20181810

Group type: EXPERIMENTAL
Intervention: Dietary products (resveratrol, green tea extract, alpha-tocopherol, vitamin C, n-3 polyunsaturated fatty acids, tomato extract)
Number of subjects: 36
Study: 18086740

Group type: EXPERIMENTAL
Intervention: Telemedicine interview (TM)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Live interview (LI)
Number of subjects: 21
Study: 21213495

Group type: EXPERIMENTAL
Intervention: Mefenamic acid, 500 mg per oral three times a day for 5 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 11715356

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neutral endopeptidase inhibitors (in combination with ACE inhibitors)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endothelin-1 antagonists
Number of subjects: 0
Study: 9642622

Group type: EXPERIMENTAL
Intervention: Copolymer-1
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study: 7626915

Group type: EXPERIMENTAL
Intervention: Inhaled bimakalim (cumulative doses of 10, 25, 40, and 100 micrograms, total cumulative dose 175 micrograms)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2510115

Group type: EXPERIMENTAL
Intervention: IgG Cutter 0.6 mg per Kg BW per week
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (35 infants with similar criteria)
Number of subjects: 35
Study: 825821

Group type: EXPERIMENTAL
Intervention: Parenteral supplementation with dextrose and amino acids (67 cal/dl formula feeding)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Oral feeding (100 cal/dl formula feeding)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Parenteral supplementation
Number of subjects: 10
Study: 31222434

Group type: EXPERIMENTAL
Intervention: Plaque-induced gingivitis group
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study: 30677539

Group type: EXPERIMENTAL
Intervention: Reslizumab
Number of subjects: 29
Study: 29049577

Group type: EXPERIMENTAL
Intervention: Behavioral intervention to reduce inappropriate antibiotic prescribing
Number of subjects: 0
Study: 26555159

Group type: EXPERIMENTAL
Intervention: Combination of danoprevir (100 mg three times daily) and mericitabine (500 mg twice daily)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Combination of danoprevir (600 mg twice daily) and mericitabine (1,000 mg twice daily)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Combination of mericitabine and ritonavir‐boosted danoprevir
Number of subjects: 72
Study: 25118055

Group type: EXPERIMENTAL
Intervention: Non-eligible patients
Number of subjects: 332

Group type: COMPARATOR
Intervention: Eligible non-randomized patients
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Non-eligible patients (adjusted)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Non-eligible patients (further adjusted)
Number of subjects: 332
Study: 21689927

Group type: EXPERIMENTAL
Intervention: Pazopanib 800mg QD
Number of subjects: 435

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 435
Study: 19614805

Group type: EXPERIMENTAL
Intervention: T80 mg plus A10 mg
Number of subjects: 1461

Group type: COMPARATOR
Intervention: A10 mg
Number of subjects: 1461

Group type: EXPERIMENTAL
Intervention: T20/A10
Number of subjects: 1461

Group type: EXPERIMENTAL
Intervention: T40/A10
Number of subjects: 1461

Group type: EXPERIMENTAL
Intervention: T80/A10
Number of subjects: 1461
Study: 17888133

Group type: EXPERIMENTAL
Intervention: Insulin Aspart (IAsp)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Regular Human Insulin (HI)
Number of subjects: 27
Study: 15173858

Group type: EXPERIMENTAL
Intervention: Epirubicin 90 mg m(‐2) plus Paclitaxel 200 mg m(‐2) (3‐h infusion) on day 1 every 3 weeks for eight courses (arm A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Epirubicin 120 mg m(‐2) on day 1 every 3 weeks for four courses followed by four courses of Paclitaxel 250 mg m(‐2) on day 1 every 3 weeks (arm B)
Number of subjects: 0
Study: 12473876

Group type: EXPERIMENTAL
Intervention: Systematic health counselling given by local public health nurses for 2 years
Number of subjects: 715

Group type: COMPARATOR
Intervention: Control group (participants with antihypertensive drug treatment)
Number of subjects: 715
Study: 10408330

Group type: EXPERIMENTAL
Intervention: Creatine
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control
Number of subjects: 25
Study: 7802586

Group type: EXPERIMENTAL
Intervention: Maximum range of motion cohort (shoulder immobilization)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Minimum range of motion cohort (no shoulder immobilization)
Number of subjects: 38
Study: 2366542

Group type: EXPERIMENTAL
Intervention: Gripping the cycle ergometer handlebar
Number of subjects: 39

Group type: COMPARATOR
Intervention: Not gripping the cycle ergometer handlebar
Number of subjects: 39
Study: 6986149

Group type: EXPERIMENTAL
Intervention: 5-thiopyridoxine (5-TP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Penicillamine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31802124

Group type: EXPERIMENTAL
Intervention: Therapeutic music video (TMV) intervention
Number of subjects: 14
Study: 31787055

Group type: EXPERIMENTAL
Intervention: Proximal LAD angioplasty
Number of subjects: 17805

Group type: COMPARATOR
Intervention: Nonproximal LAD angioplasty
Number of subjects: 17805
Study: 27136962

Group type: EXPERIMENTAL
Intervention: Argon Plasma Coagulation (APC) after Endoscopic Variceal Ligation (EVL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Observation after Endoscopic Variceal Ligation (EVL)
Number of subjects: 40
Study: 25839203

Group type: EXPERIMENTAL
Intervention: Neighbors of buyers who ordered and received a stove
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prominent community member using the efficient stove
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peer effects in opinions about efficient cookstoves
Number of subjects: 0
Study: 25492279

Group type: EXPERIMENTAL
Intervention: Simple primary closure
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rhomboid flap
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lay open group
Number of subjects: 60
Study: 22630163

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 76
Study: 19174586

Group type: EXPERIMENTAL
Intervention: Noncontact, nonthermal, low-frequency ultrasound therapy
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Silver antimicrobial dressings
Number of subjects: 11

Group type: COMPARATOR
Intervention: Water-moistened gauze
Number of subjects: 11
Study: 17380588

Group type: EXPERIMENTAL
Intervention: Sibenadet (250, 500, 750, or 1000 microg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Inhaled placebo
Number of subjects: 32
Study: 15974642

Group type: EXPERIMENTAL
Intervention: St John's wort
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Garlic oil
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Panax ginseng
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba
Number of subjects: 12
Study: 12489490

Group type: EXPERIMENTAL
Intervention: Ximelagatran (2 x 36 mg)
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Ximelagatran (2 x 24 mg daily)
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Subcutaneous LMW heparin followed by warfarin
Number of subjects: 2500
Study: 9807844

Group type: EXPERIMENTAL
Intervention: Acuplaster (BL-10, BL-11, GB-34)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 7630652

Group type: EXPERIMENTAL
Intervention: Arm Cranking (AC)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Wheelchair Propulsion on Treadmill (TM)
Number of subjects: 9
Study: 2488091

Group type: EXPERIMENTAL
Intervention: Bepridil (BEP, n = 100)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ISDN, n = 100)
Number of subjects: 200
Study: 36865

Group type: EXPERIMENTAL
Intervention: Sodium amobarbital interview
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline interview (placebo)
Number of subjects: 20
Study: 30810754

Group type: EXPERIMENTAL
Intervention: Oxycodone (OXY) 5 mg
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Ibuprofen (IBU) 600 mg
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Acetaminophen (ACE) 500 mg
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control group (non-opioid medications)
Number of subjects: 188
Study: 28750677

Group type: EXPERIMENTAL
Intervention: Inhaled AP301
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 40
Study: 26378637

Group type: EXPERIMENTAL
Intervention: Aldoxorubicin 350 mg/m2
Number of subjects: 126

Group type: COMPARATOR
Intervention: Doxorubicin 75 mg/m2
Number of subjects: 126
Study: 23514733

Group type: EXPERIMENTAL
Intervention: LY2189102 0.6 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LY2189102 18 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LY2189102 180 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LY2189102
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19575143

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC) - 10 min of ischemia followed by 15 min of reperfusion before SHVE
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Selective hepatic vascular exclusion (SHVE) - control group
Number of subjects: 84
Study: 16466554

Group type: EXPERIMENTAL
Intervention: Elective laparoscopically assisted resection
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Open resection
Number of subjects: 48

Group type: COMPARATOR
Intervention: Nonmalignant colonic disease (control group)
Number of subjects: 48
Study: 16676777

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 332

Group type: COMPARATOR
Intervention: Dysfunctional Beliefs and Attitudes about Sleep scale (DBAS)
Number of subjects: 332
Study: 14504122

Group type: EXPERIMENTAL
Intervention: 1-day quadruple therapy (4-drug regimen)
Number of subjects: 160

Group type: COMPARATOR
Intervention: 7-day triple therapy (3-drug regimen)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 160
Study: 10802469

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine infusion at 2 mL per hour
Number of subjects: 62

Group type: COMPARATOR
Intervention: Saline infusion at 2 mL per hour
Number of subjects: 62
Study: 8874303

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg, maximum dose 10 mg)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 66

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 66
Study: 1997811

Group type: EXPERIMENTAL
Intervention: Warm-up (WU)
Number of subjects: 6

Group type: COMPARATOR
Intervention: No warm-up (NWU)
Number of subjects: 6
Study: 6298318

Group type: EXPERIMENTAL
Intervention: Topical acyclovir applied six times daily for five days
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 29273207

Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (aspirin, clopidogrel, cilostazol)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (aspirin, clopidogrel, placebo)
Number of subjects: 404
Study: 28329061

Group type: EXPERIMENTAL
Intervention: Peginterferon add-on therapy (n = 39)
Number of subjects: 77

Group type: COMPARATOR
Intervention: NA monotherapy (n = 38)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Peginterferon add-on therapy (among 58 interferon-naive patients)
Number of subjects: 77

Group type: COMPARATOR
Intervention: NA monotherapy (among 58 interferon-naive patients)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Responders at week 48 who discontinued NA therapy at week 72 (n = 8)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Add-on therapy group (n = 6)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Monotherapy group (n = 2)
Number of subjects: 77
Study: 26161399

Group type: EXPERIMENTAL
Intervention: 30-minute walk in a city park for 7 consecutive days
Number of subjects: 20

Group type: COMPARATOR
Intervention: 30-minute walk on a busy urban street for 7 consecutive days
Number of subjects: 20
Study: 23287811

Group type: EXPERIMENTAL
Intervention: Individual cognitive-behavioral therapy (CBT)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Control group (waiting to be treated)
Number of subjects: 286
Study: 21215350

Group type: EXPERIMENTAL
Intervention: CB‐CIK + Chemotherapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 40
Study: 18792997

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided extracorporeal shock wave therapy (ESWT)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Subtherapeutic dose treatment
Number of subjects: 68
Study: 16421419

Group type: EXPERIMENTAL
Intervention: FOLFOX4 administered every 2 weeks until progression (arm A)
Number of subjects: 620

Group type: COMPARATOR
Intervention: FOLFOX7 for six cycles, maintenance without oxaliplatin for 12 cycles, and reintroduction of FOLFOX7 (arm B)
Number of subjects: 620
Study: 15522768

Group type: EXPERIMENTAL
Intervention: Mild head injury (MHI)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no MHI)
Number of subjects: 16
Study: 11284542

Group type: EXPERIMENTAL
Intervention: 0.5% SCN‐/0.1% H2O2 (group E)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 0.1% H2O2 (group F)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo (group A)
Number of subjects: 140
Study: 9364996

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: L-NMMA
Number of subjects: 13
Study: 8324432

Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation (0.8 mg of folic acid)
Number of subjects: 4156

Group type: COMPARATOR
Intervention: Trace elements supplement
Number of subjects: 4156
Study: 3087241

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (1 microgram X kg‐1 X min‐1)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 29356602

Group type: EXPERIMENTAL
Intervention: Diabetes sleep education program
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 31
Study: 27625060

Group type: EXPERIMENTAL
Intervention: Conservative management (observation prior to discharge)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Interventional management (insertion of a small bore drain)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Conservative management
Number of subjects: 342

Group type: COMPARATOR
Intervention: Interventional management
Number of subjects: 342
Study: 24865441

Group type: EXPERIMENTAL
Intervention: Annual multimodal screening
Number of subjects: 23374

Group type: EXPERIMENTAL
Intervention: Ultrasound screening
Number of subjects: 23374

Group type: EXPERIMENTAL
Intervention: Higher level repeat screening
Number of subjects: 23374

Group type: EXPERIMENTAL
Intervention: Ovarian cancer surgery
Number of subjects: 23374

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 23374
Study: 21667290

Group type: EXPERIMENTAL
Intervention: 30 min of exercises at 45% (easy) intensity
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 30 min of exercises at 60% (moderate) intensity
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 30 min of exercises at 75% (vigorous) intensity
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 90 min of moderate exercises
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 30, 60, and 90 min of moderate exercises
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control day
Number of subjects: 14
Study: 20640403

Group type: EXPERIMENTAL
Intervention: Metal anchors (group 1)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Biodegradable anchors (group 2)
Number of subjects: 78
Study: 18824608

Group type: EXPERIMENTAL
Intervention: BILR 355 alone (12.5 mg to 100 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BILR 355 with ritonavir (RTV) (5 mg to 87.5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19116439

Group type: EXPERIMENTAL
Intervention: Plyometric push-ups
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Medicine-ball chest passes
Number of subjects: 12

Group type: COMPARATOR
Intervention: First trial (no explosive movement)
Number of subjects: 12
Study: 12679832

Group type: EXPERIMENTAL
Intervention: Stairs Climbing (SC)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Electrostimulation (ES)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Combined Stairs Climbing and Electrostimulation (SC+ES)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (SC and ES)
Number of subjects: 32
Study: 10920696

Group type: EXPERIMENTAL
Intervention: Implementation of the Head Injury Severity Scale; routine early computerized tomography (CT) scan for mild injuries; mandatory CT scan and admission for moderate injuries.
Number of subjects: 0
Study: 8803994

Group type: EXPERIMENTAL
Intervention: Variable potassium concentration dialysis
Number of subjects: 36

Group type: COMPARATOR
Intervention: Constant potassium concentration dialysis
Number of subjects: 36
Study: 1517839

Group type: EXPERIMENTAL
Intervention: 131I‐chimeric B72.3 (IgG‐4) at total doses of 28 or 36 mCi/m2 in two or three weekly fractions
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 131I‐chimeric B72.3 (IgG‐4) at total doses of 36 mCi/m2
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 131I‐chimeric B72.3 (IgG‐4)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Second course of therapy with 131I‐chimeric B72.3 (IgG‐4)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dose fractionation of 131I‐chimeric B72.3 (IgG‐4)
Number of subjects: 12
Study: 6468471

Group type: EXPERIMENTAL
Intervention: SUR 2647 combination (2 sachets b.i.d. on the day of operation, 1 sachet b.i.d. for the following two days)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Paracetamol (2 tablets q.i.d. on the day of operation, 1 tablet q.i.d. for the following two days)
Number of subjects: 53
Study: 30417227

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 0.015 mg/ml epinephrine (Group A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2% lidocaine with 0.015 mg/ml epinephrine (Group B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4% articaine with 0.012 mg/ml epinephrine (Group C)
Number of subjects: 0
Study: 29241091

Group type: EXPERIMENTAL
Intervention: Otago exercise program (6 months)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Usual care (Control Group)
Number of subjects: 77
Study: 25676674

Group type: EXPERIMENTAL
Intervention: Lansoprazole OD 30 mg from a nasogastric tube for 14 days
Number of subjects: 120

Group type: COMPARATOR
Intervention: No treatment (Control Group)
Number of subjects: 120
Study: 25035620

Group type: EXPERIMENTAL
Intervention: Laghu Sankhaprakshalana (LSP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Back pain specific asanas (BST)
Number of subjects: 40
Study: 22257450

Group type: EXPERIMENTAL
Intervention: 12-week aerobic training program, 5 days/week, at low/moderate intensity
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no training program)
Number of subjects: 100
Study: 20040336

Group type: EXPERIMENTAL
Intervention: Bezafibrate (BF) administration
Number of subjects: 0
Study: 18346626

Group type: EXPERIMENTAL
Intervention: Auriculotherapy using magnetic pellets (experimental group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Semen vaccariae (control group)
Number of subjects: 60
Study: 15738932

Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 1249

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1249